Literature DB >> 14323662

MYASTHENIA GRAVIS: MEDICAL ASPECTS.

L R ZELDOWICZ, W S BUCKLER.   

Abstract

The diagnosis of myasthenia gravis is often difficult and calls for a broader use of pharmacological and electrodiagnostic tests. The decamethonium-edrophonium test, which has proved superior to other procedures for this purpose, is based on neurophysiological principles and depicts the behaviour of the neuromuscular junction. A state of resistance to depolarizing agents in the limited form of myasthenia and a state of a non-depolarizing (competitive) block in advanced cases has been shown. This test has demonstrated that the neuromuscular defect exists throughout the skeletal musculature, including muscles clinically unaffected. It produced no false-positive results either in normal or neurasthenic persons or in patients with neurological diseases with myasthenic symptoms. In a patient with botulism and in a patient with ocular palsies from brain-stem encephalitis the edrophonium test gave a false-positive result, while the decamethonium-edrophonium test was negative.Diagnosis, treatment and management of myasthenic emergencies are described.

Entities:  

Keywords:  ACETYLCHOLINE; BOTULISM; BROMIDES; CHOLINESTERASE INHIBITORS; CURARIFORM ANTAGONISTS; DECAMETHONIUM COMPOUNDS; DIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY; EDROPHONIUM CHLORIDE; ELECTRODIAGNOSIS; ENCEPHALITIS; MYASTHENIA GRAVIS; NEUROMUSCULAR SPINDLES; NEUROSES; PHARMACOLOGY; POTASSIUM CHLORIDE; PREGNANCY; PREGNANCY COMPLICATIONS; SPIRONOLACTONE; THYMECTOMY

Mesh:

Substances:

Year:  1965        PMID: 14323662      PMCID: PMC1928601     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  15 in total

1.  EFFECT OF DIPHENYLHYDANTOIN ON NEUROMUSCULAR SYNAPSE.

Authors:  F H NORRIS; J COLELLA; D MCFARLIN
Journal:  Neurology       Date:  1964-09       Impact factor: 9.910

2.  MULTIPLE ANTIBODY PRODUCTION IN MYASTHENIA GRAVIS.

Authors:  H VAN DER GELD; T E FELTKAMP; J VAN LOGHEM; H J OOSTERHUIS; A BIEMOND
Journal:  Lancet       Date:  1963-08-24       Impact factor: 79.321

3.  The use of lycoramine derivatives in myasthenia gravis.

Authors:  J E SOMERS; R L IRWIN; G M SHY
Journal:  Neurology       Date:  1963-07       Impact factor: 9.910

4.  Chlorpromazine-induced weakness in myasthenia gravis.

Authors:  M P MCQUILLEN; M GROSS; R J JOHNS
Journal:  Arch Neurol       Date:  1963-03

5.  Changes in serum complement activity in patients with myasthenia gravis.

Authors:  W L NASTUK; O J PLESCIA; K E OSSERMAN
Journal:  Proc Soc Exp Biol Med       Date:  1960-10

6.  Local administration of anticholinesterase agents in ocular myasthenia gravis.

Authors:  I H LEOPOLD; T R HEDGES; J MONTANA; N KRISHNA; S BECKETT
Journal:  Arch Ophthalmol       Date:  1960-03

7.  Studies in myasthenia gravis: neonatal and juvenile types.

Authors:  K E OSSERMAN; P TENG
Journal:  J Mt Sinai Hosp N Y       Date:  1956 Sep-Oct

8.  The action of decamethonium iodide (C.10) in myasthenia gravis.

Authors:  H C CHURCHILL-DAVIDSON; A T RICHARDSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1952-05       Impact factor: 10.154

9.  Obstetrics and gynaecology in relation to thyrotoxicosis and myasthenia gravis.

Authors:  G KEYNES
Journal:  J Obstet Gynaecol Br Emp       Date:  1952-04

10.  MYASTHENIA GRAVIS: ANESTHETIC AND SURGICAL MANAGEMENT OF THE PATIENT UNDERGOING THYMECTOMY.

Authors:  L C JENKINS; J CHANG; G D SAXTON
Journal:  Can Med Assoc J       Date:  1965-07-31       Impact factor: 8.262

View more
  1 in total

1.  Myasthenia gravis: comparative evaluation of medical and surgical treatment.

Authors:  L R Zeldowicz; G D Saxton
Journal:  Can Med Assoc J       Date:  1969-11-15       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.